Key result
Lower TAPSE/PASP ratio reflecting impaired RV-PA coupling is linked to in-hospital mortality in COVID-19.
Why the study?
The prognostic value of the TAPSE/PASP ratio for adverse clinical outcomes in hospitalized COVID-19 patients was not well established.
Does the TAPSE/PASP ratio predict in-hospital mortality and adverse outcomes in hospitalized patients with COVID-19?
Cohort (n=229)
Does the TAPSE/PASP ratio predict in-hospital mortality and adverse outcomes in hospitalized patients with COVID-19?
p-value: p=0.038
Impaired RV-PA coupling, assessed noninvasively via the TAPSE/PASP ratio, predicts the need for ICU-level care and in-hospital mortality in COVID-19 patients.
No takes yet. Share an insight, caveat, or question.
May refine risk stratification in hospitalized COVID-19; leaves open prospective validation before routine use.
Jani et al. (2022) conducted a cohort in COVID-19 (n=229). TAPSE/PASP ratio was evaluated on in-hospital mortality (p=0.038). A lower TAPSE/PASP ratio, indicating impaired right ventricular-pulmonary arterial coupling, was significantly associated with in-hospital mortality (p=0.038) in patients with COVID-19.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: